Fairvalue-Calculator Fairvalue-Calculator

Brother Enterprises Holding (002562) Fair Value & Analysis

Basic Materials · CN · Market cap 5.5B CNY

Price¥4.77
Fair Value¥2.07
Upside-56.6%
Quality95/100
Evidence: High Range ¥1.27 – ¥2.87

Analysis

Brother Enterprises Holding (002562) currently trades at ¥4.77, while our model-based Fair Value estimate is ¥2.07 — implying the stock looks roughly 56.6% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Brother Enterprises Holding Co.,Ltd. engages in the research, development, production, and sale of fine chemicals in China and internationally. The company offers vitamin supplements, such as vitamin K3, vitamin B1, nicotinamide, niacin, vitamin B5, and aminopropionic acid; chrome tanning agents, retanning agents, fatliquoring agents, and auxiliaries; and contrast agent APIs and intermediates, topirostat and its intermediates, and custom processing of APIs and intermediates. It also provides synthetic fragrances, including vanillin and ethyl vanillin for food, daily chemical, and other industries; molecular sieves and catalysts; and sodium dichromate, chromic acid, and chromium tanning agent. The company was formerly known as Haining Leather Chemicals Factory. Brother Enterprises Holding Co.,Ltd. was founded in 1991 and is headquartered in Haining, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.